Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 460 participants.
Also called NCT01612260
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 460 participants
- Sponsor
- Registry
-
NCT01612260
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01612260. Randomized; quadruple masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2013-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat
- Condition
- Heart Failure
- Condition
- Ventricular Premature Complex
- Intervention (Drug)
- Shensong Yangxin capsule
- Intervention (Drug)
- placebo Capsule
- Lead sponsor
- Cong-xin Huang
- Collaborator
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Collaborator
- Fudan University
- Collaborator
- Shanghai Changzheng Hospital
- Collaborator
- Nanjing Medical University
- Collaborator
- Third Military Medical University
Record details
- Record id
cardio:ct-nct01612260- Content hash
f266079cde44383001708a0b6c64a339b932748ddcf5d385640c1e42097342fa